UBS lowered the firm’s price target on Cytokinetics to $61 from $67 and keeps a Buy rating on the shares. The Data Monitoring Committee for the Phase 3 COURAGE-ALS study of reldesemtiv for amyotrophic lateral sclerosis convened to conduct the second planned interim analysis, recommending the discontinuation of the clinical study, the analyst tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CYTK:
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- 3 Best Stocks to Buy Now, 4/3/2023, According to Top Analysts
- Cytokinetics price target lowered to $59 from $61 at Cantor Fitzgerald
- Cytokinetics price target lowered to $42 from $50 at BofA
- Cytokinetics price target lowered to $49 from $56 at H.C. Wainwright
